First-line systemic therapy in patients with metastatic or locally advanced urothelial carcinoma: a systematic review and network meta-analysis of randomized controlled trials.

Ther Adv Med Oncol · 2025 · PMC12290386 · PMID 40718544

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Among the treatments with OS benefit in the overall population, nivolumab plus gemcitabine–cisplatin showed a trend of better safety than EV plus pembrolizumab in terms of all-grade TRAEs (OR 0.66, 95% CrI 0.28–1.29; Supplemental Figure 9(a) ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.